Clinical and Population Studies

Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns

Gertraud Erhart, Claudia Lamina, Terho Lehtimäki, Pedro Marques-Vidal, Mika Kähönen, Peter Vollenweider, Olli T. Raitakari, Gérard Waebler, Barbara Thorand, Konstantin Strauch, Christian Gieger, Thomas Meitinger, Annette Peters, Florian Kronenberg, Stefan Coassin

Objective—Lp(a) (lipoprotein(a)) concentrations are widely genetically determined by the LPA isoforms and show 5-fold interpopulation differences. Two- to 3-fold differences have been reported even within Europe. Finns represent a distinctive population isolate within Europe and have been repeatedly reported to present lower Lp(a) concentrations than Central Europeans. The significance of this finding was unclear for a long time because of the difficult comparability of Lp(a) assays. Recently, a large standardized study in >50000 individuals from 7 European populations confirmed this observation but could not provide insights into the causes.

Approach and Results—We investigated Lp(a) concentrations, LPA isoforms, and genotypes of established genetic variants affecting Lp(a) concentrations (LPA variants, APOE isoforms, and PCSK9 R46L) in the Finnish YFS (Cardiovascular Risk in Young Finns Study) population (n=2281) and 3 Non-Finnish Central European populations (n=10003). We observed ≈50% lower Lp(a) concentrations in Finns. The isoform distribution was shifted toward longer isoforms, and the percentage of low-molecular-weight isoform carriers was reduced. Most interestingly, however, Lp(a) was reduced in each single-isoform group. In contrast to the known inverse relationship between LPA isoforms and Lp(a) concentrations, especially very short isoforms presented unexpectedly low Lp(a) concentrations in Finns. The investigated genetic variants, as well as age, sex, and renal function, explained 71.8% of the observed population differences.

Conclusions—The population differences in Lp(a) concentrations between Finnish and Central European populations originate not only from a different LPA isoform distribution but suggest the existence of novel functional variation in the small-isoform range.

Visual Overview—An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2018;38:1230-1241. DOI: 10.1161/ATVBAHA.118.310865.)

Key Words: atherosclerosis ■ genetics, population ■ lipoprotein(a) ■ risk factors

Lp(a) (lipoprotein(a)) is a major genetically determined cardiovascular risk factor. High Lp(a) plasma concentrations are associated with coronary heart disease, myocardial infarction, aortic valve calcification and stenosis, carotid atherosclerosis, stroke, and venous thromboembolism.1,2 Lp(a) concentrations are controlled mostly genetically by the LPA locus, which encodes apo(a) (apolipoprotein(a)) as the primary structural protein of Lp(a) and explains 70% to 90% of the Lp(a) concentrations.1

The LPA gene consists of 10 different KIV (kringle IV) domains (KIV-1 to KIV-10), 1 KV domain (kringle V), and an inactive protease domain.3 The KIV-2 domain is encoded by a 5.6-kb large, coding copy number variation, which is present in 1 to >40 repeats2 and thus generates >40 isoforms in the population.3 The KIV-2 number is inversely correlated to the Lp(a) plasma concentration and explains 30% to 70% of the concentrations.1 Low-molecular-weight (LMW) isoforms (≤22 KIV repeats) are associated with ≈4- to 5-fold higher concentrations than high-molecular-weight (HMW) isoforms (>22 KIV).1 The smaller allele thus determines the LMW/HMW group assignment.4 Although >95% of the population is heterozygous on DNA, only 30% to 70% present both

Received on: December 27, 2017; final version accepted on: February 26, 2018.

From the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Austria (G.E., C.L., F.K., S.C.); Department of Clinical Chemistry, Fimlab Laboratories (T.L.), Finnish Cardiovascular Research Center (T.L., M.K.), and Department of Clinical Physiology, Tampere University Hospital (M.K.), University of Tampere, Finland; Department of Medicine, Internal Medicine, University Hospital, Lausanne University Hospital, Switzerland (P.M.-V., P.V., G.W.); Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Finland (O.T.R.); Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland (O.T.R.); Institute of Epidemiology II (B.T., C.G., A.P.), Institute of Genetic Epidemiology (K.S., C.G.), and Research Unit of Molecular Epidemiology (C.G.), Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany; German Center for Diabetes Research, Neuherberg, Germany (B.T., A.P.); Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany (K.S.); Institute of Human Genetics, Technische Universität München, Germany (T.M.); Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany (T.M.); Munich Cluster for Systems Neurology, Germany (T.M.); and German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance (A.P.).

The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.118.310865/-/DC1. Correspondence to Stefan Coassin, PhD, Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Schöpfstraße 41, A-6020 Innsbruck, Austria. E-mail stefan.coassin@t-med.ac.at

© 2018 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
isoforms also in plasma.\textsuperscript{3,5} Null alleles can be caused by large alleles, which tend to be nonexpressed or by 3 known loss-of-function (LOF) mutations.\textsuperscript{6–8}

To date, most studies did not identify Lp(a)-modifying genes outside the Lp(a) locus. Only recently, 2 additional genes were implicated into Lp(a) metabolism: \textit{APOE}\textsuperscript{9–12} and \textit{PCSK9}.\textsuperscript{13,14} The isoform \textit{APOE2} is associated with 15\% lower Lp(a) concentrations,\textsuperscript{9,10} whereas the Lp(a)-increasing effect of \textit{PCSK9} \textit{R46L} (rs11591147) with a minor allele frequency (MAF) of 3\% was associated with \textapprox 10\% lower Lp(a) concentrations in a Danish population.\textsuperscript{13}

Lp(a) concentrations show pronounced interethnical differences. In whites, Malay, Chinese, and Inuit, the distribution of Lp(a) concentration is extremely right skewed\textsuperscript{17} (median Lp(a), \textapprox 5.25 mg/dL,\textsuperscript{7} which is more frequent in Finns (MAF=0.0635) than in Tyroleans (MAF=0.053)\textsuperscript{7} or in British (PROCARDIS study [Precocious Coronary Artery Disease Study], MAF=0.03\textsuperscript{29,30}, UK Biobank, MAF=0.02).\textsuperscript{30} Also, a second rare splice-site variant (rs143431368)\textsuperscript{30} shows frequency differences between Finns and NFES (MAF, \textapprox 0.03 in Finns versus 0.003 in NFE) as reported by the Exome Aggregation Consortium (ExAC)\textsuperscript{11} and UK Biobank.\textsuperscript{30} Finally, also differences in the allele frequencies for \textit{PCSK9} R46L and APOE2 have been reported in Finns. Both are associated with reduced Lp(a),\textsuperscript{9,10,13} but, although APOE2 frequency is reduced in Finns by \textapprox 50\% and does, therefore, not contribute to the lower Lp(a) concentrations, the \textit{PCSK9} R46L LOF variant is reported to be markedly more frequent (MAF=0.179 versus 0.035 in the ExAC data).\textsuperscript{11}

To investigate the factors contributing to the population differences in Lp(a) concentrations, we report here a comprehensive investigation in a Finnish (n=2281) and 3 large Central European studies (n=56804). By combining SNP and isoform data for all samples, we assess (1) the distribution of isoforms in Finns compared with NFE and (2) dissect the relative contribution of isoforms and established Lp(a)-regulating SNPs to the low Lp(a) levels observed in Finns. Most importantly, all measurements of Lp(a) concentrations and apo(a) isoforms have been done centrally in 1 laboratory to keep methodological influences low.

### Materials and Methods

#### Populations

Details on the study populations are reported in Table 1. The CoLaus\textsuperscript{33} study (Cohorte Lausannoise) is a single-center, prospective study, including 6182 randomly selected white subjects aged 35 to 75 years from the city of Lausanne in Switzerland. Only individuals with 4 grandparents of European origin were included in the genetic study. The major aims of the CoLaus study are the investigation of prevalence and determinants of cardiovascular disease and cardiovascular risk factors in the Lausanne population. The analysis data set comprised of 3998 participants with all genotypes and Lp(a) values available.

The KORA cohorts (Cooperative Health Research in the Region of Augsburg, Cooperative Gesundheitsforschung in der Region Augsburg) are several population-based cohorts representative of the general population in Augsburg, Germany, and 2 surrounding counties. Ten-year age–sex strata have been sampled from the 25- to 74-year-old population with a stratum size of 640 subjects. The KORA F3\textsuperscript{34} study was conducted in the years 2004/2005 as a follow-up study of the KORA S3 survey (1994/1995). The KORA F4\textsuperscript{35} study was conducted in the years 2006/2008 and is a follow-up study of the KORA S4 survey (1999/2001). Both studies contain an independent nonoverlapping sample drawn from the same study region. The analyses data set comprised of 3089 participants in KORA F3 and 2916 participants in KORA F4, from which genotypes and Lp(a) values were available.

The YFS (Cardiovascular Risk in Young Finns Study)\textsuperscript{36} is a prospective multicenter study from Finland initiated in 1980 (baseline...
Children (4320) aged 3, 6, 9, 12, 15, and 18 years were randomly chosen from the population register from the 5 Finnish university cities with medical schools (Helsinki, Kuopio, Oulu, Tampere, and Turku). Several follow-ups during 30 years to investigate childhood risk factors for cardiometabolic outcomes have been performed. Lp(a) phenotype information was available for 2281 participants. The measurements included in this work have been done on materials from the follow-up in the year 2001, where 2283

| Table 1. Descriptive Statistics Continuous Variables Shown as Mean±SD and Percentiles (25%/50%/75%) |
| --- |
| **Age, y** | YFS (n=2281)* | NFE (n=10003)* | CoLaus (n=3998)* | KORA F3 (n=3089)* | KORA F4 (n=2916)* |
| | 31.70±4.99 (27/33/36) | 55.60±12.25 (46/55/65) | 58.54±10.52 (49/58/66) | 57.32±12.90 (46/57/67) | 56.16±13.30 (44/56/67) |
| **Women, n (%)** | 1255 (55.0%) | 5230 (52.3%) | 2141 (53.6%) | 1584 (51.3%) | 1505 (51.6%) |
| **Lp(a), mg/dL; all subjects** | 12.45±5.29 (2.78/6.32/15.19) | 22.47±26.09 (5.07/11.94/31.51) | 23.37±26.82 (7.67/56.54/78.59) | 50.68±34.22 (18.34/49.39/72.48) | 47.57±31.12 (22.27/46.59/66.08) |
| **Lp(a), mg/dL; LMW isoforms** | 34.23±22.31 (15.62/33.54/46.56) | 52.64±33.24 (28.28/50.75/71.93) | 51.59±33.27 (37.67/56.54/78.59) | 50.68±34.22 (18.34/49.39/72.48) | 47.57±31.12 (22.27/46.59/66.08) |
| **Lp(a), mg/dL; HMW isoforms** | 8.36±8.86 (2.36/5.28/11.18) | 13.60±14.50 (4.02/8.91/17.30) | 13.92±14.71 (4.00/9.20/18.16) | 13.39±14.56 (4.00/8.64/16.55) | 13.36±14.14 (4.00/8.83/17.25) |
| **LMW isoform carriers, n (%)** | 361 (15.8%) | 2272 (22.7%) | 846 (21.2%) | 707 (22.9%) | 719 (24.7%) |
| **LDL cholesterol, mg/dL** | 126.8±32.6 (104.4/123.7/147.0) | 132.6±34.9 (108.3/131.0/154.7) | 133.6±36.3 (108.3/131.5/158.6) | 128.0±32.6 (105.0/126.0/148.0) | 136.1±34.9 (110.0/134.0/158.0) |
| **LDL-C corrected, mg/dL‡** | 123.0±32.3 (100.11/119.7/142.3) | 125.8±34.6 (101.7/124.1/147.7) | 126.5±35.9 (101.5/125.3/149.8) | 121.4±32.4 (98.7/119.9/141.6) | 129.5±34.5 (104.9/127.6/151.7) |
| **HDL cholesterol, mg/dL** | 49.9±12.3 (41.0/49.1/57.6) | 59.9±17.1 (47.0/58.0/69.6) | 63.7±18.1 (50.3/61.9/73.5) | 58.8±17.1 (46.0/56.0/69.0) | 55.9±14.4 (45.0/54.0/65.0) |
| **Total cholesterol, mg/dL** | 199.7±38.0 (174.0/197.2/224.3) | 218.6±40.1 (192.0/216.6/243.6) | 220.9±40.3 (193.4/220.4/247.5) | 218.2±40.0 (191.0/216.0/243.0) | 216.0±40.0 (188.0/214.0/240.0) |
| **Triglycerides, mg/dL§** | 119±76 (71/94/172) | 135±100 (77/99/194) | 120±78 (71/94/172) | 125±89 (72/105/151) | 125±89 (72/105/151) |
| **Type-2 diabetes mellitus, n (%)** | 78/2266 (3.4%) | 912/9994 (9.1%) | 436/3996 (10.9%) | 240/3082 (7.8%) | 236/2916 (8.1%) |
| **eGFR, mL/min per 1.73 m²** | 109.7±11.3 (102.6/111.8/117.6) | 85.4±16.6 (74.7/86.9/97.2) | 81.7±14.9 (71.9/82.2/92.3) | 87.9±17.6 (78.2/90.7/100.3) | 87.7±16.9 (77.3/89.1/100.0) |

| **SNP MAF/APOE haplotype frequency** |
| --- |
| rs143431368 (LPA) | 0.027 | 0.002 | 0.002 | 0.002 | 0.002 |
| rs41272114 (LPA) | 0.049 | 0.031 | 0.034 | 0.029 | 0.028 |
| rs3798220 (LPA) | 0.012 | 0.015 | 0.015 | 0.016 | 0.014 |
| rs10455872 (LPA) | 0.029 | 0.056 | 0.056 | 0.053 | 0.060 |
| rs11591147 (PCSK9) | 0.039 | 0.013 | 0.010 | 0.015 | 0.016 |
| rs7412 (APOE) | 0.043 | 0.068 | 0.052 | 0.084 | 0.073 |
| rs429358 (APOE) | 0.195 | 0.131 | 0.128 | 0.136 | 0.132 |
| APOE2/E2 | 0.001 | 0.003 | 0.001 | 0.006 | 0.004 |
| APOE2/E3 | 0.062 | 0.111 | 0.089 | 0.130 | 0.121 |
| APOE2/E4 | 0.020 | 0.018 | 0.013 | 0.026 | 0.016 |
| APOE3/E3 | 0.580 | 0.640 | 0.669 | 0.611 | 0.632 |
| APOE3/E4 | 0.302 | 0.210 | 0.213 | 0.209 | 0.207 |
| APOE4/E4 | 0.034 | 0.017 | 0.015 | 0.018 | 0.020 |

eGFR indicates estimated glomerular filtration rate; HDL, high-density lipoprotein; HMW, high molecular weight; KIV, kringle IV; KORA, Cooperative Health Research in the Region of Augsburg, Kooperative Gesundheitsforschung in der Region Augsburg; LDL, low-density lipoproteins; LDL-C, low-density lipoprotein cholesterol; LMW, low-molecular weight; Lp(a), lipoprotein(a); MAF, minor allele frequency; NFE, Non-Finnish Central European; SNP, single nucleotide polymorphisms; and YFS, Cardiovascular Risk in Young Finns Study.

*Based on samples with available Lp(a) concentration.
†Shorter isoform present.
‡LDL cholesterol levels corrected for Lp(a) concentrations.55
§KORA F3 participants were nonfasting.
individuals (63.5% of the original cohort) participated in clinical examinations, and 2620 (72.9%) returned questionnaires. Informed consent was obtained from each participant, and the studies were approved by the respective institutional review boards.

**Lp(a) Quantification Using ELISA**

Lp(a) plasma concentrations were measured using a sandwich ELISA method described by Kronenberg et al with minor modifications. All measurements were done in the same laboratory (Division of Genetic Epidemiology, Medical University of Innsbruck, Austria).

In brief, the ELISA plates (Nunc-Immuno MicroWell Maxi Sorp flat bottom design, MaxiSorp surface treatment; Thermo Fisher Scientific, Waltham) were coated using an affinity-purified polyclonal rabbit anti-human apo(a) antibody in a final concentration of 5 µg/mL in 1x PBS containing 1 mg/mL NaCl. The plates were incubated with 100 µL antibody dilution (3 hours, 37°C), washed 3x (1x PBS+0.05% v/v Tween-20), and blocked with 200-µL 0.1% wt/vol casein in 1x PBS pH 7.3 (30 minutes, 37°C). To ensure measuring each sample within the linear range of optical density, all samples were diluted into the ELISA plate twice (1:150 and 1:1500 in Assay Buffer [Microcoat, Bernried, DE]) of 1:30 and 1:1000 predilutions in 1x PBS, pH 7.3. A 7-point standard curve ranging from 0.32 mg/dL to 5 µg/dL was created (with an additional blank representing the zero point). Duplicate determinations of 4 reference samples were used as longitudinal interassay controls.

The coated plates were incubated with the analyte for 1 hour at 37°C. Detection was performed using a horseradish peroxidase-conjugated monoclonal antibody (1A2 in 0.1% wt/vol casein, 1x PBS, pH 7.3) directed against the KIV domain and not cross-reacting with conjugated monoclonal antibody (1A2; in 0.1% wt/vol casein, 1× PBS, pH 7.3). A 7-point standard curve ranging from 0.32 mg/dL to 5 µg/dL was created (with an additional blank representing the zero point). Duplicate determinations of 4 reference samples were used as longitudinal interassay controls.

The coated plates were incubated with the analyte for 1 hour at 37°C. Detection was performed using a horseradish peroxidase-conjugated monoclonal antibody (1A2 in 0.1% wt/vol casein, 1x PBS, pH 7.3) directed against the KIV domain and not cross-reacting with plasminogen (1 hour, 37°C). After 3 washing steps as described above, 100 µL Blue Star TMB substrate (Adaltis, Guidonia Montecelio, IT) was added (30 minutes, room temperature). Reaction was stopped by adding 50 µL 0.5 mol/L sulfuric acid. Measurement of the absorption (dual wavelength, analyte: 450 nm, reference: 690 nm) was done using a Microplate Reader (BioRad Benchmark Plus; Bio-Rad Laboratories, Hercules), and concentrations were calculated based on the standard curve (expressed as mg/dL). All dilution and pipetting steps were done using liquid handling robotics (Tecan, Männedorf, CH).

**apo(a) Isoform Determination by Western Blot**

apo(a) isoform determination has been done as previously described in Kronenberg et al with minor modifications. All measurements were done in the same laboratory (Division of Genetic Epidemiology, Medical University of Innsbruck, Austria) and evaluated by the same experienced scientist.

In brief, Lp(a) concentrations of each sample were determined by ELISA as described above, and all plasma samples were then diluted with PBS to a standardized Lp(a) concentration of 30 ng/L. Ten microliters of this dilution were mixed with 20 µL of reducing sample buffer (15.38% v/v glycerol, 7.69% 2-mercaptoethanol, 3.85% v/v SDS, 0.177% v/v 4-ethylymorpholine, and 0.077% wt/vol bromophenol blue) resulting in an Lp(a) concentration of 10 ng/mL. Protein was denatured at 98°C for 5 minutes. Subsequently, 150 ng (15 µL of the 10-ng/mL solution) were applied on the gel to obtain an equal apo(a) mass. A size standard consisting of a mixture of 5 plasma samples expressing only 1 apo(a) isoform each (13, 19, 23, 27, and 35 KV repeats, determined by pulsed-field gel electrophoresis) was applied every seventh sample on the gel to detect uneven gel running and minimize distance between samples and standards. After electrophoresis, the proteins were transferred to a polyvinylidenefluoride membrane (Immobilon-P; Millipore, Darmstadt, DE) using semidyrd blotting (Perfect Blue Semi Dry Blotter; VWR, Vienna, Austria). The membrane was first equilibrated in methanol for 30 seconds, and then rinsed in water and afterward equilibrated in blotting buffer (20% v/v ethanol, 16 mmol/L Tris, and 120 mmol/L glycine). The transfer was done for 45 minutes and 250 mA having the blotting stack semidyry in Blotting Buffer. The membrane was then blocked for at least 30 minutes at 37°C using buffer C (85 mmol/L NaCl, 10 mmol/L Tris, 0.2% Triton X-100, and 1% BSA) and incubated in the first antibody (1A2 in a concentration of 168 ng/mL in buffer C) for 2 hours at room temperature on a shaker. After 3 wash steps in TTBS (Tris-buffered saline buffer with Tween-20, 20 mmol/L Tris-HCl pH 7.4, 0.5 mol/L NaCl, and 0.05% Tween-20) at 15 minutes each, the membrane was incubated with horseradish peroxidase-conjugated goat anti-mouse antibody (401253, Millipore, Darmstadt, DE; diluted 1:13333 in buffer C) for 45 minutes on a shaker at room temperature. Residual secondary antibodies were removed by 3 washing steps (15 minutes in TTBS each); enhanced chemiluminescence substrate (WesternBright Chemiluminescence Spray; Biozym, Hessisch Oldendorf, DE) was added, and the signals were detected on an Amersham Hyperfilm for enhanced chemiluminescence (GE Healthcare, Vienna, Austria).

**Genotyping**

1000 Genomes imputed-genome-wide genotyping data were available for CoLaus and YFS, whereas genotypes imputed using the haplotype reference consortium panel were available for KORA F3 and KORA F4. These data were used for evaluation of LPA SNPs rs3798820, rs10455872, rs143431368, and rs41272114, as well as PCSK9 rs11591147 (PCS9 K46L) and the APOE isoforms E2, E3, and E4 (rs7412 and rs249358). APOE haplotypes are defined as follows: APOE2/E2: rs7412=TT and rs249358=TT, APOE2/E3: rs7412=CT and rs249358=TT, APOE2/E4: rs7412=CT and rs249358=CT, APOE3/E3: rs7412=CC and rs249358=CT, APOE3/E4: rs7412=CC and rs249358=CT, APOE4/E4: rs7412=CC and rs249358=CT. Imputation quality is given in Table VII in the online Data Supplement and in Mack et al 2017.

**Statistical Methods**

In samples heterozygous for apo(a) isoforms, the smaller of the 2 isoforms present is commonly used for assignment to the LMW (≤22 KIV) or the HMW (>22 KIV) groups.4 Because genotyping using pulsed-field gel electrophoresis is not feasible on population scale, we refer to the Western blot result throughout the article, when assigning zygosity. For statistical analysis and data presentation of heterozygous samples, the smaller isoform present was termed isoform 1, independent of its size, and the larger isoform was named isoform 2. Accordingly, all isoform-based adjustments and stratifications were done based on the smaller isoform (unless otherwise stated).

Because of the skewed distribution of the Lp(a) trait, nonparametric tests were used to compare median values of Lp(a) between the studies (Mann–Whitney–Wilcoxon test, Dunn post hoc test for multiple comparisons was used to test for significant median differences between all possible pairwise tests between studies. Proportions were tested by χ2 test. In regression and mediation models, inverse-normal transformation was used for Lp(a) to adhere to the normal distribution assumption for statistical tests. Equal distribution of isoforms within carriers of rs10455872 and rs3798820 in YFS and NFE was tested using the Kolmogorov–Smirnov test.

We used a multivariable regression model to evaluate the joint influence of the SNPs rs10455872, rs3798820, rs143431368, rs41272114, and rs11591147, APOE2 and APOE4 carriers, the isoforms (isoform 1), age, sex, and estimated glomerular filtration rate (eGFR) on Lp(a). Imputed genotype scores were used on a continuous scale, which corresponds to an additive coding. The eGFR was included to account for renal function, which is one of the few established nongenetic modifiers of Lp(a) concentrations. eGFR was calculated according to Levey et al,42 CDK EPI [Chronic Kidney Disease Epidemiology Collaboration] creatinine equation. For the isoforms, a nonlinear transformation was performed accounting for the evaluated variables, we performed a formal
mediation analysis. This means that the effect on Lp(a) of being Finnish is decomposed into the effect portions, which are mediated by the isoforms, by the SNPs, and by other factors, which differ between YFS and the Non-Finnish European studies (see the Results section). Because the participants in the YFS are younger than the participants in the other Non-Finnish studies, age and, in consequence, better kidney function could also possibly explain the difference in Lp(a) distribution. Therefore, eGFR and age were also included as potential mediating variables. Technically, a binary variable (Finnish versus Non-Finnish) was created and regressed onto inverse-normal transformed Lp(a) values. This effect is denoted as the total effect. Then, this simple regression model was adjusted for the potential mediating variables (age, sex, eGFR, isoform 1, and the investigated SNPs). The percentage by which the total effect is attenuated is the relative mediated effect, which can be decomposed into their single parts (indirect effects, herein referred to as explained effects). The remaining effect is the direct effect of the variable being Finnish. This is actually the remainder, which cannot be explained by the included variables (herein referred to as unexplained effects). Assumptions of the mediation model are (1) association of the mediators with the outcome (this was set to a P value <0.1) and (2) association of the exposure (the Finnish versus Non-Finnish effect) with the outcome (P value, <0.1). Only those variables were included in the mediation analysis that fulfilled these assumptions. Model assumptions, decomposition into single indirect effects (time of resampling, n=100), and bootstrap confidence intervals (number of times of bootstrap resampling, n=500) were performed using the package mma in R. All statistical analyses were done with R (http://www.r-project.org).

Results

YFS Present Reduced Lp(a) Concentrations Compared With Central Europeans

We determined Lp(a) concentrations and apo(a) isoforms in the YFS (n=2281) and in the 3 Central European population CoLaus (n=3998), KORA F3 (n=3089), and KORA F4 (n=2916). All measurements were performed in the same laboratory using standardized ELISA and Western blot assays. Median Lp(a) concentrations were similar in all Central European populations (P=0.59 for all pairwise comparisons between Central European populations) but significantly different between YFS and all Central European studies (Figure 1A; Table I in the online-only Data Supplement; all P≤1.38×10−58 for all pairwise comparisons using Dunn post hoc test). Therefore, for all subsequent analyses, CoLaus, KORA F3, and KORA F4 were combined to the Non-Finnish Europeans (NFE) population. The median Lp(a) concentration in YFS was significantly lower than in NFE (6.3 versus 11.6 mg/dL; P=8.15×10−91; Figure 1A). This difference was present both in men and women and when restricting the analysis only to the age range ≥32 to ≤39 years allowing a similar age distribution of all studies (Table I in the online-only Data Supplement). When stratifying Lp(a) concentrations into 5-mg/dL strata, concentrations of 0 to 5 mg/dL were overrepresented in YFS compared with NFE (42.3% versus 24.7%; P=5.22×10−64; Figure 1B). Accordingly, less individuals showed concentrations >30 mg/dL and >50 mg/dL, which are commonly deemed as thresholds for increased cardiovascular risk (≥30 mg/dL, 12.1% versus 25.3%; ≥50 mg/dL, 3.9% versus 14.1%; P=2.32×10−44 and P=1.17×10−41; Figure III in the online-only Data Supplement).

Differences in Isoform Distributions Between YFS and NFE

The Lp(a) concentration is highly dependent on the number of KIV repeats. We, therefore, investigated whether the apo(a) isoform distribution is shifted toward larger isoforms in YFS compared with NFE, which could potentially explain the lower Lp(a) levels observed in YFS.

Isoforms ≤25 KIV repeats were more frequent in NFE than in YFS, whereas YFS presented higher frequencies of isoforms with ≥28 KIV domains (Figure 2A). Accordingly, LMW frequency was significantly reduced in YFS compared with the NFE populations (361/2282 [15.8%] versus 2272/10003 [22.7%]; P=5.83×10−13; Figure 2B). The median size of the smaller isoform (isoform 1) was larger in YFS than in NFE (29 versus 27 KIV repeats; P=8.21×10−12; Figure 2C; Table II in the online-only Data Supplement). In heterozygous individuals, the differences in the distribution of the larger isoform (isoform 2) were less pronounced but still significant (36 versus 35 KIV repeats; P=3.54×10−12; Figure 2D; Table II in the online-only Data Supplement).

Interestingly, the Lp(a) concentrations were lower in YFS than in NFE even within the LMW and HMW groups (Figure 3A). Because this could arise from a shift of the isoform distribution toward higher isoforms within the groups (thus reducing the group mean without changing group assignment), we stratified the Lp(a) isoforms into more granular subgroups as done in earlier studies.47 YFS showed reduced Lp(a) concentrations in all subgroups (Figure 3B; Table IV in the online-only Data Supplement). Also, the percentage of homozygous null allele carriers (ie, samples that do not present any of the 2 LPA isoforms in plasma as detectable by Western blotting) was higher in YFS than in NFE (n=36 [1.6%] versus n=70 [0.7%]; P=7.25×10−5). However, the median Lp(a) concentration of the entire YFS cohort increased only marginally from 6.32 to 6.46 mg/dL after exclusion of the homozygous null allele carriers.

Frequency of Established Lp(a)-Regulating SNPs

The APOE isoforms and PCSK9 R46L have been recently established as novel genetic regulators of Lp(a).9,10,13 As described in detail in the Introduction section, both genetic variants show differences in allele frequencies between Finns and Central Europeans. The same applies to 2 well-known LPA splice-site variants6,7 (Table 1). We, therefore, evaluated to which extent these variants contribute to the differences in Lp(a) concentrations between YFS and NFE. YFS presented a higher frequency of E3/E4 and E4/E4 (P=3.72×10−30 and P=1.04×10−6, respectively) and lower frequencies of E2/E3 (P=1.41×10−11; Table 1). Conversely, rs11591147, rs143431368, and rs41272114 were more frequent in YFS than in NFE (Table 1; P=4.79×10−29, P=6.77×10−43, and P=1.44×10−4, respectively). They represent, therefore, valid putative determinants for the observed differences in Lp(a).

Moreover, the LPA variants rs379822048 and rs1045587248, which have been reported to tag small isoforms (19–21 and 17–20 KIV repeats, respectively),48 were included. Both showed the same isoform distribution in YFS as in NFE (P=0.61 and
Erhart et al  Genetic Factors Lower Lp(a) in Finns

1235

The rs10455872 frequency was ≈50% lower in YFS (which is also in line with the lower frequency of short isoforms), whereas no pronounced frequency difference was observed for the rarer rs3798220 variant.

Association of Potential Mediating Factors With Lp(a) Concentrations

We investigated LPA isoform distribution, LPA and PCSK9 LOF frequencies, and APOE isoform frequencies, as well as sex, age, and renal function, estimated by eGFR 1.5 as potential mediators of the observed population differences. Results from multiple regression models for each factor on Lp(a) are reported in Table 2 (YFS and NFE) and Table V in the online-only Data Supplement (single studies). Among the genetic factors, isoforms were highly associated with Lp(a) in a nonlinear fashion (Figure 4), whereas APOE2 and the SNPs rs143411368 and rs41272114, which are more frequent in the YFS, showed an Lp(a)-decreasing effect. Conversely, rs10455872 and rs378220 were associated with increased Lp(a), but only rs10455872 shows a pronounced frequency difference between YFS and NFE and thus potentially contributes to the Lp(a) difference. No association was observed for PCSK9 R46L (rs11591147) and APOE4.
carrier status, despite their frequency difference between YFS and NFE.

The multiple adjusted effect of isoform 1 on Lp(a) is shown in Figure 4. In general, Lp(a) decreases with increasing KIV repeats, although not linearly. Because in YFS the distribution of isoforms is shifted to higher repeat numbers, lower Lp(a) values are expected. Both in YFS and NFE, Lp(a) decreases rather sharply at >22 repeats. The nonlinear relationship is consistent in all 3 Non-Finnish studies and is also consistent for HMW isoforms in YFS. Interestingly, the effect of isoform 1 being <20 KIV repeats on Lp(a) concentrations differs between YFS and NFE. Although in NFE the Lp(a) concentrations still rise for isoforms <20, the Lp(a) values decrease in YFS.

Among the study-specific factors, age and female sex were associated with increased Lp(a) values, whereas eGFR, which is higher in the YFS, was associated with a decreased Lp(a) (although not significantly). Because YFS individuals are younger and present better renal function than those in the NFE studies, Lp(a) values are lower in YFS also in consequence of the age effect.

Mediation Analysis Explaining the Differences in Lp(a) Concentrations Between Finns and Non-Finns

The multiple regression model (Table 2) indicates that both genetic and environmental factors, which are associated with reduced Lp(a) and which are more frequent in YFS than in NFE, contribute to lowering Lp(a) in YFS. To identify the relative contribution of these factors, we conducted a formal mediation analysis. All variables of the multiple regression models were included as potential mediators of the “Finns effect” on Lp(a), except SNP rs11591147, which was not significant in the multiple regression model and thus did not fulfill the criteria to be included as a mediator (Table VI in the online-only Data Supplement), and rs3798220, which was not identified as an independent modifier (Table VII in the online-only Data Supplement; column P value 2). Altogether, 71.8% of the Finns effect is determined by the included mediators, which leaves 28.2% unexplained (Figure 5). The largest contributors to reduced Lp(a) concentrations in YFS are the isoforms (27.3%), followed by age (26.4%), eGFR (10.4%), rs41272114 (4.0%), and rs143411368 (3.8%), whereas APOE2 frequency contributed inversely (−1.8%).

Figure 2. apo(a) (apolipoprotein(a)) isoform distribution in YFS (Cardiovascular Risk in Young Finns Study) and Non-Finnish Central Europeans (NFE). A, Isoform 1 in YFS and NFE stratified by groups of 3 KIV (kringle IV) repeats (except the group with shortest isoforms 11–16). YFS shows a higher frequency of carriers >28 KIV repeats, compared with NFE. The number of carriers in each isoform stratum is given in Table IV in the online-only Data Supplement. B, Low-molecular-weight (LMW; at least 1 isoform with ≤22 KIV repeats) and high-molecular-weight (HMW) carriers (only isoforms with >22 repeats) in YFS and NFE. HMW individuals are more common in YFS. \( P = 5.83 \times 10^{-13} \). C and D, apo(a) isoform distribution of the 2 alleles. The violin plots show distributions of the smaller allele (isoform 1) and the larger allele (isoform 2, if detectable). The isoform distribution in YFS is shifted toward larger alleles. Diamonds, median; black dots, 25th and 75th percentiles; red dots, 10th and 90th percentiles. For details and unclustered NFE data, see Figure IV in the online-only Data Supplement and Table III in the online-only Data Supplement.
Lp(a) concentrations show pronounced interethnic and interpopulation variability. Several reports showed lower Lp(a) concentrations in Finns than in other European populations, but the small sample numbers of early studies and the nonstandardized Lp(a) quantification methods hampered a direct comparison. Waldeyer et al recently confirmed lower median Lp(a) concentrations (≈−58%) in the Finnish FINRISK cohort compared with Central European populations (NFE). The nonclustered populations are shown in Figure V in the online-only Data Supplement. We found that in YFS, the Lp(a) concentrations were reduced even within the same-isoform group. This mirrors the differences between blacks and whites, where blacks present higher Lp(a) concentrations than NFE individuals in all isoform groups. In the group 11 to 19 KIV repeats, Finns have an even lower Lp(a) concentration than in the larger 17 to 19 KIV repeats group. Stratified number of carriers for each population and median Lp(a) concentrations are given in Tables IV and V in the online-only Data Supplement and Figure VI in the online-only Data Supplement.

Figure 3. Lp(a) (lipoprotein(a)) concentrations stratified by apo(a) (apolipoprotein(a)) isoform size. A, Median Lp(a) concentration stratified by low-molecular-weight (LMW)/high-molecular-weight (HMW) classification. In both groups, YFS (Cardiovascular Risk in Young Finns Study) presents lower median Lp(a) concentrations than Non-Finnish Central Europeans (NFE). The nonclustered populations are shown in Figure V in the online-only Data Supplement. B, Median Lp(a) concentrations stratified by isoform size in groups of 3 to 5 KIV (kringle IV) isoforms (based on isoform 1). YFS individuals express lower Lp(a) concentrations than NFE individuals in all isoform groups. In the group 11 to 16 KIV repeats, Finns have an even lower Lp(a) concentration than in the larger 17 to 19 KIV repeats group. Stratified number of carriers for each population and median Lp(a) concentrations are given in Tables IV and V in the online-only Data Supplement and Figure VI in the online-only Data Supplement.

We found that a consistent part of the differences in Lp(a) concentrations can be explained by the common action of (1) isoform distribution, (2) LPA variants, and (3) APOE genotypes. Additionally, we observed that in Finns, the Lp(a) concentrations were reduced in all apo(a) isoform groups.

The isoform distribution in Finns was shifted toward longer isoforms (Figure 2), which accounted for 27% of the interpopulation differences in Lp(a) concentrations (Figure 5). It thus represents the largest contributor to the interpopulation differences without being, however, the only causal factor. This is in line with previous reports showing that differences in isoform distribution among populations only partially account for interpopulation differences in Lp(a) concentrations.1,5

Figure 4. Nonlinear spline, showing the effect of isoform 1 (ie, in heterozygotes, the smaller allele present) on untransformed Lp(a) (lipoprotein(a)) concentrations. The splines are centered at 0 at isoform 1=27 (median on the Non-Finnish Central Europeans studies). The splines are derived from the multiple regression model additionally adjusting for the variables age, sex, estimated glomerular filtration rate, rs143411368, rs412727114, rs11591147, APOE2, and APOE4-carriers (Table V in the online-only Data Supplement). The spline for inverse-transformed Lp(a) is shown in Figure VIII in the online-only Data Supplement. YFS, Cardiovascular Risk in Young Finns Study; KORA, Cooperative Health Research in the Region of Augsburg, Kooperative Gesundheitsforschung in der Region Augsburg; KIV, kringle IV.

We found that in YFS, the Lp(a) concentrations were reduced even within the same-isoform group. This mirrors the differences between blacks and whites, where blacks present higher Lp(a) concentrations over the whole range of isoforms.17,20 The effect was most striking in the 11 to 16 KIV repeats group, which showed even lower Lp(a) than the 17 to 19 KIV repeats group (Figures 3B and 4). Finns have a higher frequency of LOF mutations and variants in conserved noncoding regions than Central Europeans.6,51 Because LPA is reported to be LOF tolerant by ExAC (according to the pLI/pRec scores on the ExAC website13) and by phenome-wide studies,10 and it has been shown that Lp(a)-modifying SNPs can cluster with particular isoforms3,52; it is tempting to speculate that novel functional variants may exist in the 11 to 16 KIV repeat carriers in YFS. Indeed, especially short isoforms according to the Western blot might represent truncated protein forms caused by novel nonsense or splice-site variants. Such truncated forms have been observed previously in Tyroleans with low Lp(a).8
Several studies proposed that (even frequent) SNPs contribute to interethnic differences in Lp(a) levels. The APOE isoforms vary between Finns and Central Europeans, with APOE2 being rarer and APOE4 being more frequent in Finns. Although the individual impact of these genetic variants on Lp(a) has been described previously, their cumulative contribution in establishing low Lp(a) levels in Finns has not been evaluated to date. We showed that the frequency distribution of 2 LPA LOF variants and rs10455872 contributed for a total of ≈10% to the population difference. Conversely, APOE2 counteracts this by increasing Lp(a) and so contributes to closing the gap between the populations (Figure 5; Table VI in the online-only Data Supplement). Among the APOE genotypes, only APOE2 showed an appreciable contribution in the mediation analysis in this sample set, which is in line with previous results (Figure 5; Table VI in the online-only Data Supplement). Among the APOE genotypes, only APOE2 showed an appreciable contribution in the mediation analysis in this sample set, which is in line with previous results\(^{10}\) (Figure 5; Table VI in the online-only Data Supplement). Of note, rs41272114—a major contributor in our mediation analysis—has been proposed also as a cause for the Lp(a) differences between whites and Africans\(^{54}\). No effect of rs11591147 was found, which is likely because of its small absolute effects on Lp(a) concentrations (1 mg/dL).\(^{13}\) We could also not confirm the high MAF (17.9%) of rs11591147 reported in Finns by ExAC (Table 1), but we rather support the MAF determined in the SISu (Sequencing Initiative in Suomi) project (4.2%).\(^{6}\)

Importantly, the focus of the work at hands was to show that the observed differences in Lp(a) are not just because of a shifted isoform distribution and evaluate the contribution of known functional factors affecting Lp(a) concentrations. This left ≈28% of variance unexplained and suggests the existence of additional functional variation. Various types of genetic variants may contribute to this observation. The KIV-2 region plays a special role because it encompasses a considerable part of the LPA gene but is currently not captured by common genetic data set. However, also differences in the effect magnitude or frequency of known variation outside the KIV-2 may play role. Comparative ultradeep sequencing studies and a
dedicated study design will be required to pinpoint the genetic determinants of the population differences reported here.

**Strengths and Limitations**

Our study presents strengths and limitations. To the best of our knowledge, here we present the largest investigation of Lp(a) concentrations in European populations accounting for Lp(a) isoform data to date. All measurements and Western blots were done in a single laboratory using the same methods in all populations. The YFS individuals are younger and present better renal function—a major determinant of Lp(a) levels—than the NFE. Accordingly, environmental differences account for 34% of the population differences, and age and eGFR were the second largest contributors to the population differences. This underscores the importance of matching these factors, despite the often alleged robustness Lp(a) to nongenetic influences.

The pronounced effect of age is surprising and could reflect kidney function parameters, which are not reflected by eGFR, other unmeasured age-related confounders (eg, hormonal status), or undetermined study-specific confounders, which are specific for the YFS study. The difference between YFS and NFE is present in both sexes (Table I in the online-only Data Supplement) and also when looking only at the age range ≥32 to ≤39, where all studies overlap. This indicates that the observed Lp(a) reduction is not only because of different proportion of postmenopausal individuals in NFE. Finally, it has to be noted that the mediation analysis assumes a linear and homogeneous effect of the factors. Therefore, the differing effect of low isoforms on Lp(a) in YFS cannot be fully accounted for and may contribute to the unexplained effect.

Importantly, no other study with combined information on Lp(a) concentrations and isoform distribution in Finns was available until now, except 1 small study in 181 individuals. We could successfully identify and quantify determinants of the Lp(a) differences between Finns and NFE and show that a limited number of genetic elements (isoforms and SNPs) already explain remarkable ≈37% of the population difference. This may indicate that a small number of factors can already explain a consistent part of differences of Lp(a) between Finns and NFE populations. Finally, the availability of Western blot data allowed identifying a surprising Lp(a)-lowering effect in short isoforms in YFS, which warrants further research.

**Conclusion**

We demonstrate that the lower Lp(a) concentrations in Finns are not caused solely by differences in isoform distribution but are lowered across the whole range of isoforms. Frequency differences of common LOF mutations and APOE isoforms significantly contribute to these findings but do not fully explain it. Of particular note, especially very small isoforms with 11 to 16 KIV repeats present massively lowered Lp(a) concentrations, which might hint toward the existence of novel LOF mutations. Therefore, future sequencing studies in LPA might be fruitful to identify novel Lp(a)-lowering variants.

**Acknowledgments**

This work was part of the bachelor thesis in Biomedical Sciences of G. Erhart at the Health University of Applied Sciences Tyrol.

**Sources of Funding**

This study was supported by the Austrian Science Fund (FWF) Project Number P266600-B13 to C. Lamina. Other funding sources are given in the online-only Data Supplement.

**Disclosures**

None.

**References**

1. Kronenberg F, Utermann G. Lipoprotein(a); resurrected by genetics. *J Intern Med*. 2013;273:6–30. doi: 10.1111/j.1365-2796.2012.02592.x.

2. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res*. 2016;57:1953–1975. doi: 10.1194/jlr.R071233.

3. Schmidt K, Noureon A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). *J Lipid Res*. 2016;57:1339–1359. doi: 10.1194/jlr.R067314.

4. Enquoll S, Thompson A, Di Angelantonio E, Saleheen D, Kaphtoe S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. *J Am Coll Cardiol*. 2010;55:2160–2167. doi: 10.1016/j.jacc.2009.10.080.

5. Enkhmaa B, Amurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. *J Lipid Res*. 2016;57:1111–1125. doi: 10.1194/jlr.R051904.

6. Lim ET, Wurzt P, Havulinna AS, et al; Sequencing Initiative Suomi (SISu) Project. Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet*. 2014;10:e1004494. doi: 10.1371/journal.pgen.1004494.

7. Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital Lp(a) deficiency: a frequent apo(a) ‘null’ mutation in caucasians. *Hum Mol Genet*. 1999;8:2087–2096. doi: 10.1038/hmg.8.11.2087.

8. Parson W, Kraft HG, Niederstätter H, Lingenhel AW, Köchl S, Fresser F, Utermann G. A common nonsense mutation in the repetitive kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). *Hum Mutat*. 2004;24:474–480. doi: 10.1002/humu.20101.

9. Moriarthy PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431,239 patients. *Arterioscler Thromb Vasc Biol*. 2017;37:580–588. doi: 10.1161/ATVBHA.116.308704.

10. Mack S, Coassin S, Ruedi R, et al; KORA-Study Group. A genome-wide association study on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. *J Lipid Res*. 2017;58:1834–1844. doi: 10.1194/jlr.M076232.

11. Amurad E, Lu G, Rubin J, Pearson TA, Berglund L. ApoE genotype affects allele-specific apo(a) levels for large apo(a) sizes in African Americans: the Harlem-Basset Study. *J Lipid Res*. 2007;48:693–698. doi: 10.1016/j.jlr.M076232.

12. Li J, Lange LA, Sabourin J, Duan Q, Valdar W, Willis MS, Li Y, Wilson JG, Lange EM. Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study. *Hum Genet*. 2015;60:755–761. doi: 10.1038/hg.2015.107.

13. Langsted A, Nordestgaard BG, Benn M, Tybjerg-Hansen A, Kamstrup PR, PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis. *J Clin Endocrinol Metab*. 2016;101:3281–3287. doi: 10.1210/jc.2016-1206.

14. Ramognuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. *J Biol Chem*. 2015;290:11649–11662. doi: 10.1074/jbc.M114.611988.

15. Tiet L, de Knijff P, Menzel HJ, Elhohm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European
Atherosclerosis Research Study. Arterioscler. Thromb. 1994;14:1617–1624. doi: 10.1161/01.ATV.14.10.1617.

16. Reyes-Soffer G, Pavlíly M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipid metabolism in healthy humans. Circulation. 2017;135:352–362. doi: 10.1161/CIRCULATIONAHA.116.025253.

17. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lacker C, Császár A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607–614.

18. Marcovina SM, Albers JJ. Lipoprotein(a) measurements for clinical application. J Lipid Res. 2016;57:526–537. doi: 10.1194/jlr.R0606148.

19. Scholz M, Kraft HG, Lingenhel A, Delpont R, Vorster EH, Bickeböller H, Utermann G. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet. 1999;7:169–178. doi: 10.1038/sj.ejhg.5200290.

20. Helmhold M, Bigge J, Muche R, Mainno J, Thiery J, Seidel D, Armstrong TB, Bigge J, Muche R, Mainno J, Thiery J, Seidel D. Armstrong VW. Contribution of the apo[a] phenotype to plasma Lp(a) concentrations shows considerable ethnic variation. J Lipid Res. 1991;32:1919–1928.

21. Salmela E, Lappalainen T, Fransson I, Andersen PM, Dahlman-Wright K, Fiebig A, Sistonen P, Savontaus ML, Schreiber S, Kere J, Laerhoven P. Genome-wide analysis of single nucleotide polymorphisms uncovers population structure in Northern Europe. PLoS One. 2008;3:e3519. doi: 10.1371/journal.pone.0003519.

22. Lao O, Lu TT, Notthagel M, et al. Correlation between genetic and environmental factors to lipoprotein(a) concentrations. J Lipid Res. 2008;49:1241–1248. doi: 10.1194/jlr.M800346.

23. Salomaa V, Rasi V, Kallithalinali S, Vahtera E, Jauhiainen M, Ehnholm C, Pekkanen J. Hemostatic factors as predictors of coronary events and total mortality: the FINRISK ‘92 Hemostasis Study. Arterioscler Thromb Vasc Biol. 2002;22:353–358.

24. Kivimäki M, Magnusson CG, Juonala M, Kähönen M, Kettunen J, Loo BM, Lehtimäki T, Viikari J, Raitakari OT. Conventional and Mendelian randomization studies suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study. Int J Epidemiol. 2011;40:470–478. doi: 10.1093/ijep/esy045.

25. Leino A, Impivaara O, Kaittasaari M, Järvisaari M, Järvisalo J. Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Clin Chem. 1995;41:1633–1636.

26. Kunutsor SK, Khan H, Nyyssonen K, Laukkanen JA. Lipoprotein(a) and risk of sudden cardiac death in middle-aged Finnish men: a new prospective cohort study. Int J Cardiol. 2016;220:718–725. doi: 10.1016/j.ijcard.2016.06.069.

27. Klauser IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Study Group. Arterioscler Thromb Vasc Biol. 1995;15:1001–1008. doi: 10.1161/01.ATV.15.8.1001.

28. Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2016;37:1443–1448. doi: 10.1093/eurheartj/ehw484.

29. Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol. 2014;18:234–237. doi: 10.1007/s10157-013-0875-8.

30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.

31. Kamprust HR, Tybjærg-Hansen A, Stöfflens R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339. doi: 10.1001/jama.2009.801.

32. Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853. doi: 10.1093/eurheartj/ehq386.

33. Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantrier B, Stadler M, Peters A, Koenig W, Stockl A, Dähnhardt D, Böger CA, Krämer BK, Friedrich G, Strauch K, Kronenberg F. Lipoprotein(a) concentrations, apolipoprotein(a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res. 2014;103:28–36. doi: 10.1093/cvr/cvu107.

34. Clarke R, Reder P, Hopewell JC, et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528. doi: 10.1056/NEJMoa0902604.

35. Ogorelkova M, Kraft HG, Ehnholm C, Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringle IV types 6 to 10 downregulate Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet. 2001;10:815–824. doi: 10.1093/hmg/10.8.815.

36. Gao W, Boerwinkle E, Cohen JC, Hobbis BB. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common “null” allele at the apo(a) locus. J Clin Invest. 1994;93:2526–2534. doi: 10.1172/JCI17263.

37. Chobd A, Palta P, Pirinen M, McCarthy S, Goriček GR, munch R, Kukkinen S, Salomaa V, Daly M, Durbin R, Palotie A, Aittokallio T, Ripatti S. Whole-genome views of the consequence of a population bottleneck using 2926 genome sequences from Finland and the United Kingdom. Eur J Hum Genet. 2017;25:477–484. doi: 10.1038/ejhg.2016.205.

38. Coalson S, Erhart G, Weissennstein H, et al. A novel but frequent variant in LPA KIV-2 is associated with a pronounced hyperlycosopheric locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992;90:220–230. doi: 10.1007/BF00220606.

39. Kronenberg F, Küchel S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hyperlycosopheric locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992;90:220–230. doi: 10.1007/BF00220606.

40. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR, 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;524:68–74. doi: 10.1038/nature15193.

41. Kronenberg F, Küchel S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hyperlycosopheric locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992;90:220–230. doi: 10.1007/BF00220606.

42. Kronenberg F, Küchel S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hyperlycosopheric locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992;90:220–230. doi: 10.1007/BF00220606.
Erhart et al  Genetic Factors Lower Lp(a) in Finns

53. Deo RC, Wilson JG, Xing C, Lawson K, Kao WH, Reich D, Tandon A, Akyildiz E, Patterson N, Mosley TH Jr, Boerwinkle E, Taylor HA Jr. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. *PLoS One*. 2011;6:e14581. doi: 10.1371/journal.pone.0014581.

54. Chretien JP, Coresh J, Berthier-Schaad Y, Kao WH, Fink NE, Klag MJ, Marcovina SM, Giaculli F, Smith MW. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. *J Med Genet*. 2006;43:917–923. doi: 10.1136/jmg.2006.042119.

55. Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. *Clin Chim Acta*. 2011;412:1783–1787. doi: 10.1016/j.cca.2011.05.036.

**Highlights**

- Lp(a) (lipoprotein(a)) concentrations are massively reduced by ≈50% in Finns (n=2281) compared with Central Europeans (n=10003).
- Finns presented a shift in apo(a) isoform distribution toward larger isoforms and frequency differences in established Lp(a)-regulating genetic variants (*LPA* loss-of-functions, *APOE*, and *PCSK9*).
- Lp(a) was reduced over the whole isoform range. Of particular note, very small isoforms showed surprisingly low Lp(a) concentrations.
- 71.8% of the differences between the populations can be explained by a combination of genetic and environmental factors.